The Experts below are selected from a list of 681 Experts worldwide ranked by ideXlab platform
Naveen Babu K - One of the best experts on this subject based on the ideXlab platform.
-
Research Article CODEN: IJPNL6 FORMULATION AND EVALUATION OF CONTROLLED POROSITY OSMOTIC DRUG DELIVERY SYSTEM OF Metoprolol Succinate
2015Co-Authors: Usha Sri T, Rajesh Vooturi, Vishnu P, Naveen Babu KAbstract:Controlled porosity osmotic tablet of Metoprolol Succinate prepared and evaluated in this study. Metoprolol Succinate is very low soluble drug. So it is difficult to formulate osmotic tablet of Metoprolol Succinate which gives drug release up to 24 hr at zero order. To get desired dissolution profile various formulation parameters like osmogen concentration, level of weight gain and level of pore former concentration were studied. Final optimized formulation was studied for effect of pH of dissolution media, agitation. There is no effect of pH of dissolution media and agitation intensity on dissolution. There is significant effect of osmotic pressure on dissolution confirms that prepared Metoprolol Succinate tablet gives drug release with osmotic mechanism
-
formulation and evaluation of controlled porosity osmotic drug delivery system of Metoprolol Succinate
International Journal of Pharmacy, 2014Co-Authors: Usha Sri T, Rajesh Vooturi, P Vishnu, Naveen Babu KAbstract:Controlled porosity osmotic tablet of Metoprolol Succinate prepared and evaluated in this study. Metoprolol Succinate is very low soluble drug. So it is difficult to formulate osmotic tablet of Metoprolol Succinate which gives drug release up to 24 hr at zero order. To get desired dissolution profile various formulation parameters like osmogen concentration, level of weight gain and level of pore former concentration were studied. Final optimized formulation was studied for effect of pH of dissolution media, agitation. There is no effect of pH of dissolution media and agitation intensity on dissolution. There is significant effect of osmotic pressure on dissolution confirms that prepared Metoprolol Succinate tablet gives drug release with osmotic mechanism.
Jennifer Sugg - One of the best experts on this subject based on the ideXlab platform.
-
Metoprolol Succinate extended release hydrochlorothiazide combination tablets
Vascular Health and Risk Management, 2007Co-Authors: James W Hainer, Jennifer SuggAbstract:Lowering elevated blood pressure (BP) with drug therapy reduces the risk for catastrophic fatal and nonfatal cardiovascular events such as stroke and myocardial infarction. Given the heterogeneity of hypertension as a disease, the marked variability in an individual patient's BP response, and low response rates with monotherapy, expert groups such as the Joint National Committee (JNC) emphasize the value of combination antihypertensive regimens, noting that combinations, usually of different classes, have additive antihypertensive effects. Metoprolol Succinate extended-release tablet is a beta-1 (cardio-selective) adrenoceptor-blocking agent formulated to provide controlled and predictable release of Metoprolol. Hydrochlorothiazide (HCT) is a well-established diuretic and antihypertensive agent, which promotes natruresis by acting on the distal renal tubule. The pharmacokinetics, efficacy, and safety/tolerability of the antihypertensive combination tablet, Metoprolol extended release hydrochlorothiazide, essentially reflect the well-described independent characteristics of each of the component agents. Not only is the combination product more effective than monotherapy with the individual components but the combination product allows a low-dose multidrug regimen as an alternative to high-dose monotherapy, thereby, minimizing the likelihood of dose-related side-effects.
-
a factorial study of combination hypertension treatment with Metoprolol Succinate extended release and felodipine extended release results of the Metoprolol Succinate felodipine antihypertension combination trial m fact
American Journal of Hypertension, 2006Co-Authors: William H Frishman, James W Hainer, Jennifer SuggAbstract:Background Many hypertensive patients require combination therapy to achieve target blood pressure (BP). β-Blockers and dihydropyridine calcium channel blockers are effective as monotherapy in hypertensive patients and have complementary mechanisms for lowering BP. Methods This multicenter, randomized, placebo-controlled, unbalanced factorial study included a 4- to 5-week single-blind placebo, 9-week, double-blind treatment as well as a 2-week double-blind, down-titration period. Patients ( N = 1092) were randomized to one of 16 treatment groups: extended-release (ER) Metoprolol Succinate (25, 100, or 400 mg), ER felodipine (2.5, 10, or 20 mg), ER felodipine/ER Metoprolol Succinate (2.5/25, 2.5/100, 2.5/400, 10/25, 10/100, 10/400, 20/25, 20/100, or 20/400 mg), or placebo. Results At baseline, treatment groups were well balanced; mean sitting BP was 152.6/99.9 mm Hg. Monotherapy with ER Metoprolol Succinate induced dose-related reductions in sitting systolic/diastolic BP (DBP) (mean 8.1/7.7 to 9.7/11.1 mm Hg) as did ER felodipine (mean 7.7/7.7 to 14.0/11.8) and the combinations reflected additive effects (mean 13.8/11.0 to 19.8/15.2). The decline in the placebo group was 2.1/4.0 mm Hg. All combinations were more effective than their components ( P Conclusions The antihypertensive effects of ER Metoprolol Succinate and ER felodipine are dose-related, and when given in combination, their BP-lowering effects are additive over a wide dose range. Low-dose combination therapy is comparable in effectiveness to high-dose monotherapy but is better tolerated.
Usha Sri T - One of the best experts on this subject based on the ideXlab platform.
-
Research Article CODEN: IJPNL6 FORMULATION AND EVALUATION OF CONTROLLED POROSITY OSMOTIC DRUG DELIVERY SYSTEM OF Metoprolol Succinate
2015Co-Authors: Usha Sri T, Rajesh Vooturi, Vishnu P, Naveen Babu KAbstract:Controlled porosity osmotic tablet of Metoprolol Succinate prepared and evaluated in this study. Metoprolol Succinate is very low soluble drug. So it is difficult to formulate osmotic tablet of Metoprolol Succinate which gives drug release up to 24 hr at zero order. To get desired dissolution profile various formulation parameters like osmogen concentration, level of weight gain and level of pore former concentration were studied. Final optimized formulation was studied for effect of pH of dissolution media, agitation. There is no effect of pH of dissolution media and agitation intensity on dissolution. There is significant effect of osmotic pressure on dissolution confirms that prepared Metoprolol Succinate tablet gives drug release with osmotic mechanism
-
formulation and evaluation of controlled porosity osmotic drug delivery system of Metoprolol Succinate
International Journal of Pharmacy, 2014Co-Authors: Usha Sri T, Rajesh Vooturi, P Vishnu, Naveen Babu KAbstract:Controlled porosity osmotic tablet of Metoprolol Succinate prepared and evaluated in this study. Metoprolol Succinate is very low soluble drug. So it is difficult to formulate osmotic tablet of Metoprolol Succinate which gives drug release up to 24 hr at zero order. To get desired dissolution profile various formulation parameters like osmogen concentration, level of weight gain and level of pore former concentration were studied. Final optimized formulation was studied for effect of pH of dissolution media, agitation. There is no effect of pH of dissolution media and agitation intensity on dissolution. There is significant effect of osmotic pressure on dissolution confirms that prepared Metoprolol Succinate tablet gives drug release with osmotic mechanism.
Masoor Kamalesh - One of the best experts on this subject based on the ideXlab platform.
-
effect of carvedilol vs Metoprolol Succinate on mortality in heart failure with reduced ejection fraction
American Heart Journal, 2018Co-Authors: Tarek Ajam, Samer Ajam, Srikant Devaraj, Kahee A Mohammed, Stephen G Sawada, Masoor KamaleshAbstract:Abstract Background Beta blocker therapy is indicated in all patients with heart failure with reduced ejection fraction (HFrEF) as per current guidelines. The relative benefit of carvedilol to Metoprolol Succinate remains unknown. This study aimed to compare survival benefit of carvedilol to Metoprolol Succinate. Methods The VA’s databases were queried to identify 114,745 patients diagnosed with HFrEF from 2007 to 2015 who were prescribed carvedilol and Metoprolol Succinate. The study estimated the survival probability and hazard ratio by comparing the carvedilol and Metoprolol patients using propensity score matching with replacement techniques on observed covariates. Sub-group analyses were performed separately for men, women, elderly, duration of therapy of more than 3 months, and diabetic patients. Results A total of 43,941 Metoprolol patients were matched with as many carvedilol patients. The adjusted hazard ratio of mortality for Metoprolol Succinate compared to carvedilol was 1.069 (95% CI: 1.046-1.092, P value: Conclusion Patients with HFrEF taking carvedilol had improved survival as compared to Metoprolol Succinate. The data supports the need for furthering testing to determine optimal choice of beta blockers in patients with heart failure with reduced ejection fraction.
Bhanudas S. Kuchekar - One of the best experts on this subject based on the ideXlab platform.
-
development and validation of a stability indicating rp hplc method for simultaneous estimation of olmesartan medoxomil and Metoprolol Succinate in pharmaceutical dosage form
Pharmaceutical methods, 2012Co-Authors: Nirmal M Thakker, Haresh B Panchal, Dinesh R Rakholiya, R Murugan, Vishnu P Choudhari, Bhanudas S. KuchekarAbstract:Aim and Backrgound: A simple, rapid, precise and isocratic RP‑HPLC (Reverse Phase High Performance Liquid Chromatography) method is aimed to develop for the simultaneous estimation of Olmesartan Medoxomil and Metoprolol Succinate in bulk drug and pharmaceutical dosage form. Materials and Methods: The quantification is carried out using YMC‑Pack CN (250 × 4.6 mm, 5.0 μm) column and the mobile phase comprises of 0.05% Trifluoro acetic acid (TFA) and Acetonitrile (ACN) (70:30 v/v). The flow rate is 1.0 ml/min. The eluent is monitored at 220 nm. The retention times of Olmesartan Medoxomil and Metoprolol Succinate are 7.9 min and 4.1 min respectively. The method is validated in terms of linearity, precision, accuracy, specificity, limit of detection and limit of quantitation. Results: Linearity and percentage recoveries of both Olmesartan Medoxomil and Metoprolol Succinate are in the range of 5‑35 μg/ml and 100 ± 2%, respectively. The stress testing of both the drugs individually and their mixture is carried out under acidic, alkaline, oxidation, photo‑stability and thermal degradation (dry heat and wet heat) conditions and its degradation products are well resolved from the analyte peaks. Conclusion: This method was successfully validated for accuracy, precision, and linearity. Key words: HPLC, Metoprolol Succinate, Olmesartan Medoxomil, stability indicating method.
-
Pulsatile multiparticulate drug delivery system for Metoprolol Succinate
Archives of Pharmacal Research, 2011Co-Authors: Swati C. Jagdale, Sachin M. Chede, Ram Gulwady, Bhanudas S. Kuchekar, Pradeep D. Lokhande, Tejas P. Shah, Anuruddha R. ChabukswarAbstract:Cardiovascular diseases and their treatment pose a great challenge. Many instances of cardiovascular disease occur in the early morning hours. Hence, the objective of this study was to develop a time-controlled release formulation of Metoprolol Succinate based on a pulsatile multiparticulate (pellets) drug delivery system. The formulation was intended to be administered in the evening at 22:00 hours to evaluate symptoms of cardiovascular disease that are experienced in the early morning hours (from 04:00 to 06:00). Drug layering followed by a swelling layer and finally by an insoluble coat application was done using a Sanmour fluid bed processor. Metoprolol Succinate layered on sugar pellets (74% w/w) layered with 20% (w/w) ion doshion resin P-547 and coated with 15% (w/w) ethocel with the addition of 20% castor oil showed a lag time of 4 h and was then followed a sigmoidal release pattern with more than 95% drug having been released by the 10^th h.
-
development and optimization of Metoprolol Succinate gastroretentive drug delivery system
Acta Pharmaceutica, 2010Co-Authors: Sanjay P Boldhane, Bhanudas S. KuchekarAbstract:Metoprolol Succinate (MS) gastroretentive (GR) controlled release system was formulated to increase gastric residence time leading to improved drug bioavailability. Box-Behnken model was followed using novel combinations of sodium alginate (SA), sodium carboxymethylcellulose (NaCMC), magnesium alumino metasilicate (MAS) as independent variables. Floating lag time (Flag), t 25 , t 50 , t 75 , diffusion exponent as dependent variables revealed that the amount of SA, NaCMC and MAS have a significant effect (p < 0.05) on t 25 , t 50 , t 75 and Flag. MSGR tablets were prepared and evaluated for mass, thickness, hardness, friability, drug content and floating property. Tablets were studied for dissolution for 24 h and exhibited controlled release of MS with floating for 16 h. The release profile of the optimized batch MS01 fitted first--order kinetics (R 2 = 0.9868, n = 0.543), indicating non--Fickian diffusion or anomalous transport by diffusion and swelling.